Spotlight on Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®) in the Prevention of Premalignant Genital Lesions, Genital Cancer, and Genital Warts in Women

被引：0
|
作者：
Paul L. McCormack
Elmar A. Joura
机构：
[1] Adis,Department of Obstetrics and Gynaecology, Division of Gynaecologic Oncology
[2] a Wolters Kluwer Business,undefined
[3] Medical University of Vienna,undefined
来源：
BioDrugs | 2011年 / 25卷
关键词：
Human Papilloma Virus; Genital Wart; Seroconversion Rate; Human Papilloma Virus Vaccine; Human Papilloma Virus Type;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Quadrivalent human papilloma virus (HPV) [types 6, 11, 16, 18] recombinant vaccine (Gardasil®; Silgard®) is composed of virus-like particles (VLPs) formed by self-assembly of recombinant L1 capsid protein from each of HPV types 6, 11, 16, and 18. The VLPs are noninfectious, containing no DNA, and are highly immunogenic, inducing high levels of neutralizing antibodies against the particular HPV types when administered to animals or humans. Quadrivalent HPV vaccine is indicated for use from the age of 9 years for the prevention of premalignant genital lesions (cervical, vulvar, and vaginal), cervical cancer, and external genital warts (condyloma acuminata) causally related to certain oncogenic or specific HPV types.
引用
收藏
页码：339 / 343
页数：4
相关论文
共 42 条
  • [41] Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial
    Hu, Yue-Mei
    Bi, Zhao-Feng
    Zheng, Ya
    Zhang, Li
    Zheng, Feng-Zhu
    Chu, Kai
    Li, Ya-Fei
    Chen, Qi
    Quan, Jia-Li
    Hu, Xiao-Wen
    Huang, Xing-Cheng
    Zhu, Kong-Xin
    Wang-Jiang, Ya-Hui
    Jiang, Han -Min
    Zang, Xia
    Liu, Dong-Lin
    Yang, Chang -Lin
    Pan, Hong-Xing
    Zhang, Qiu-Fen
    Su, Ying-Ying
    Huang, Shou-Jie
    Sun, Guang
    Huang, Wei-Jin
    Huang, Yue
    Wu, Ting
    Zhang, Jun
    Xia, Ning-Shao
    SCIENCE BULLETIN, 2023, 68 (20) : 2448 - 2455
  • [42] Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial
    Chu, Kai
    Bi, Zhao-Feng
    Huang, Wei-Jin
    Li, Ya-Fei
    Zhang, Li
    Yang, Chang-Lin
    Jiang, Han -Min
    Zang, Xia
    Chen, Qi
    Liu, Dong-Lin
    Pan, Hong-Xing
    Huang, Yue
    Zheng, Feng-Zhu
    Zhang, Qiu-Fen
    Sun, Guang
    Su, Ying-Ying
    Huang, Shou-Jie
    Pan, Hui-Rong
    Wu, Ting
    Hu, Yue-Mei
    Zhang, Jun
    Zhu, Feng-Cai
    Xia, Ning-Shao
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2023, 34
12345